Aestus Therapeutics, Inc.
http://www.aestustherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aestus Therapeutics, Inc.
AstraZeneca Strengthens Diabetes R&D With Option On Astellas/Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
Deals Shaping The Medical Industry (11/2011)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Novel Pain Therapeutics: When Will Life Get Better On The Island Of Pain?
Nothing has arguably hurt pharmaceutical investors and dealmakers quite so often and with such force as novel pain drug development failures. As a result, a once hot field has gone cold. Despite setbacks, great strides have been made in understanding the complex biology of pain. Scientists have discovered numerous new pain pathway targets with the potential for designing effective agents with fewer off-target effects. Improvements that make preclinical studies more predictive of clinical success are also opening up new opportunities. At the same time, drug developers now understand better how to design drug trials that can segment patient populations to demonstrate therapeutic efficacy more precisely, potentially reducing placebo effects and paving the way for an era of personalized pain medicine.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice